Ophthotech Announces Appointment of David E. Redlick to Its Board of Directors

NEW YORK–(BUSINESS WIRE)–Ophthotech Corporation (Nasdaq: OPHT) today announced the appointment of
David E. Redlick to its Board of Directors effective immediately.

David Redlick recently retired as a Partner in the Corporate Practice
Group at Wilmer Cutler Pickering Hale and Dorr LLP (WilmerHale), an
international law firm. Mr. Redlick joined WilmerHale in 1975 and has
served as the co-chair of the Life Sciences Group, the co-chair of the
Corporate Department and a member of the firm’s Executive Committee. Mr.
Redlick’s legal practice focused on corporate and securities law, with
an emphasis on public offerings, mergers and acquisitions, venture
capital transactions and corporate collaborations. For over 40 years,
Mr. Redlick served as counsel for a broad range of clients, including
public and private life sciences and high technology companies,
investment banks, venture capital funds and real estate development and
finance companies. Mr. Redlick also currently serves as a special
advisor at Leerink Partners LLC, an investment bank focused exclusively
on the healthcare industry.

“We welcome David to Ophthotech’s Board of Directors during this
exciting time as we continue to move our product pipeline forward and
prepare for data from our two ongoing Phase 3 trials of Fovista®
in combination with Lucentis® for the treatment of wet
age-related macular degeneration in the fourth quarter of this year,”
stated David R. Guyer, M.D., Chief Executive Officer and Chairman of the
Board of Ophthotech. “David’s many accomplishments and experience as a
leading practitioner in the life sciences industry at an international
law firm will bring valued insight to our Board as we seek to execute
our plan to bring Fovista® to market as quickly as possible
and advance our product pipeline.”

“This is an exciting time for Ophthotech,” stated David E. Redlick. “I
am particularly pleased by the opportunity to share my experience in the
life sciences with the Company. I look forward to working closely with
the other Board members and supporting the Company’s management team to
build sustainable shareholder value.”

About Ophthotech Corporation

Ophthotech is a biopharmaceutical company specializing in the
development of novel therapeutics to treat back of the eye diseases,
with a focus on developing innovative therapies for age-related macular
degeneration (AMD). Ophthotech’s most advanced product candidate, Fovista®
anti-PDGF therapy, is in Phase 3 clinical trials for use in combination
with anti-VEGF therapy that represents the current standard of care for
the treatment of wet AMD. Ophthotech’s second product candidate, Zimura®,
an inhibitor of complement factor C5, is being developed for the
treatment of geographic atrophy, a form of dry AMD. For more
information, please visit www.ophthotech.com.

Forward-looking Statements

Any statements in this press release about Ophthotech’s future
expectations, plans and prospects constitute forward-looking statements
for purposes of the safe harbor provisions under the Private Securities
Litigation Reform Act of 1995. Forward-looking statements include any
statements about Ophthotech’s strategy, future operations and future
expectations and plans and prospects for Ophthotech, and any other
statements containing the words “anticipate,” “believe,” “estimate,”
“expect,” “intend”, “goal,” “may”, “might,” “plan,” “predict,”
“project,” “target,” “potential,” “will,” “would,” “could,” “should,”
“continue,” and similar expressions. In this press release, Ophthotech’s
forward looking statements include statements about the timing and
progress of the Fovista® Phase 3 clinical program, including the timing
of obtaining initial, topline data from these trials, the timing of
potential marketing approval for Fovista® and the potential of Fovista®
as a wet AMD combination therapy. Such forward-looking statements
involve substantial risks and uncertainties that could cause
Ophthotech’s clinical development programs, future results, performance
or achievements to differ significantly from those expressed or implied
by the forward-looking statements. Such risks and uncertainties include,
among others, those related to the initiation and conduct of clinical
trials, availability of data from clinical trials and expectations for
regulatory approvals or other actions and other factors discussed in the
“Risk Factors” section contained in the quarterly and annual reports
that Ophthotech files with the SEC. Any forward-looking statements
represent Ophthotech’s views only as of the date of this press release.
Ophthotech anticipates that subsequent events and developments will
cause its views to change. While Ophthotech may elect to update these
forward-looking statements at some point in the future, Ophthotech
specifically disclaims any obligation to do so except as required by law.

OPHT-G

Contacts

Investors
Ophthotech Corporation
Kathy Galante,
212-845-8231
Vice President, Investor Relations and Corporate
Communications
kathy.galante@ophthotech.com
or
Media
SmithSolve
LLC on behalf of Ophthotech Corporation
Jennifer Devine,
973-442-1555 ext. 102
jennifer.devine@smithsolve.com